Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
Here we review the insights and lessons learned from early clinical trials of T-cell engaging bispecific antibodies (BsABs) as a new class of biotherapeutic drug candidates with clinical impact potential for the treatment of multiple myeloma (MM). BsABs are capable of redirecting host T-cell cytotox...
Saved in:
Main Author: | Fatih M. Uckun |
---|---|
Format: | article |
Language: | EN |
Published: |
Frontiers Media S.A.
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/11695cf4ab3a40e68a0db44dd99e9bf0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer
by: Sultan Tousif, et al.
Published: (2021) -
T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
by: Daisuke Kamakura, et al.
Published: (2021) -
Role of Extracellular Vesicle-Based Cell-to-Cell Communication in Multiple Myeloma Progression
by: Ilaria Saltarella, et al.
Published: (2021) -
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
by: Fatih M. Uckun, et al.
Published: (2021) -
Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma
by: Braham MVJ, et al.
Published: (2018)